The stock of Biogen Inc (BIIB) has gone up by 0.29% for the week, with a -2.04% drop in the past month and a 9.08% rise in the past quarter. The volatility ratio for the week is 3.19%, and the volatility levels for the past 30 days are 2.64% for BIIB. The simple moving average for the past 20 days is -1.51% for BIIB’s stock, with a -3.67% simple moving average for the past 200 days.
Is It Worth Investing in Biogen Inc (NASDAQ: BIIB) Right Now?
The price-to-earnings ratio for Biogen Inc (NASDAQ: BIIB) is 28.12x, which is above its average ratio. Moreover, the 36-month beta value for BIIB is -0.04. Analysts have varying opinions on the stock, with 13 analysts rating it as a “buy,” 8 as “overweight,” 11 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BIIB is 144.48M and currently, short sellers hold a 2.12% of that float. On July 04, 2024, BIIB’s average trading volume was 1.14M shares.
BIIB) stock’s latest price update
The stock of Biogen Inc (NASDAQ: BIIB) has decreased by -1.62 when compared to last closing price of 228.82. Despite this, the company has experienced a 0.29% gain in its stock price over the last five trading sessions. accesswire.com reported 2024-07-03 that NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid=89068&wire=1 or contact Joseph E. Levi, Esq.
Analysts’ Opinion of BIIB
Many brokerage firms have already submitted their reports for BIIB stocks, with Needham repeating the rating for BIIB by listing it as a “Buy.” The predicted price for BIIB in the upcoming period, according to Needham is $300 based on the research report published on February 14, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see BIIB reach a price target of $240, previously predicting the price at $315. The rating they have provided for BIIB stocks is “Equal Weight” according to the report published on February 14th, 2024.
UBS gave a rating of “Neutral” to BIIB, setting the target price at $276 in the report published on January 24th of the current year.
BIIB Trading at 1.13% from the 50-Day Moving Average
After a stumble in the market that brought BIIB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.72% of loss for the given period.
Volatility was left at 2.64%, however, over the last 30 days, the volatility rate increased by 3.19%, as shares sank -4.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.71% upper at present.
During the last 5 trading sessions, BIIB rose by +0.07%, which changed the moving average for the period of 200-days by -11.85% in comparison to the 20-day moving average, which settled at $228.09. In addition, Biogen Inc saw -13.00% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BIIB starting from Singhal Priya, who sale 93 shares at the price of $213.09 back on Apr 02 ’24. After this action, Singhal Priya now owns 4,886 shares of Biogen Inc, valued at $19,817 using the latest closing price.
Singhal Priya, the Head of Development of Biogen Inc, sale 262 shares at $221.23 during a trade that took place back on Feb 22 ’24, which means that Singhal Priya is holding 4,886 shares at $57,962 based on the most recent closing price.
Stock Fundamentals for BIIB
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.73 for the gross margin
The net margin for Biogen Inc stands at 0.12. The total capital return value is set at 0.06. Equity return is now at value 8.04, with 4.56 for asset returns.
Based on Biogen Inc (BIIB), the company’s capital structure generated 0.3 points at debt to capital in total, while cash flow to debt ratio is standing at 0.25. The debt to equity ratio resting at 0.43. The interest coverage ratio of the stock is 5.33.
Currently, EBITDA for the company is 2.6 billion with net debt to EBITDA at 2.45. When we switch over and look at the enterprise to sales, we see a ratio of 4.03. The receivables turnover for the company is 4.79for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.10.
Conclusion
To wrap up, the performance of Biogen Inc (BIIB) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
